Esmeralda Casas-Silva

Esmeralda Casas-Silva

Auto-generated profile, based on publicly available information

Esmeralda Casas-Silva

Center for Biomedical Informatics and Information Technology, NCI, Rockville, Maryland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Cell Genomics
Verified
Journal Article
Open access
HHeidi Rehm
Heidi Rehm
APAngela J.H. Page
Angela J.H. Page
LSLindsay Smith
Lindsay Smith
JAJeremy B. Adams
Jeremy B. Adams
GAGil Alterovitz
Gil Alterovitz
EBEwan Birney
Ewan Birney
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits.

1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RTRatna R. Thangudu
Ratna R. Thangudu
MHMichael Holck
Michael Holck
DSDeepak Singhal
Deepak Singhal
APAlexander Pilozzi
Alexander Pilozzi
NENathan John Edwards
Nathan John Edwards
XZXu Zhang
Xu Zhang
Proteomics has emerged as a powerful tool for studying cancer biology, developing diagnostics, and therapies. With the continuous improvement and widespread availability of high-throughput proteomic technologies, the generation of large-scale proteomic data has become more common in cancer research, and there is a growing need for resources that support the sharing and integration of multi-omics datasets. Such datasets require extensive metadata including clinical, biospecimen, and experimental and workflow annotations that are crucial for data interpretation and reanalysis. The need to integrate, analyze, and share these data has led to the development of NCI’s Proteomic Data Commons (PDC), accessible at https://pdc.cancer.gov. As a specialized repository within the NCI Cancer Research Data Commons (CRDC), PDC enables researchers to locate and analyze proteomic data from various cancer types and connect with genomic and imaging data available for the same samples in other CRDC nodes. Presently, PDC houses annotated data from more than 160 datasets across 19 cancer types, generated by several large-scale cancer research programs with cohort sizes exceeding 100 samples (tumor and associated normal when available). In this article, we review the current state of PDC in cancer research, discuss the opportunities and challenges associated with data sharing in proteomics, and propose future directions for the resource. Significance: The Proteomic Data Commons (PDC) plays a crucial role in advancing cancer research by providing a centralized repository of high-quality cancer proteomic data, enriched with extensive clinical annotations. By integrating and cross-referencing with complementary genomic and imaging data, the PDC facilitates multi-omics analyses, driving comprehensive insights, and accelerating discoveries across various cancer types.

15 March 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
ZWZhining Wang
Zhining Wang
TDTanja M. Davidsen
Tanja M. Davidsen
GKGina R. Kuffel
Gina R. Kuffel
KAKanakaDurga Addepalli
KanakaDurga Addepalli
ABAmanda Bell
Amanda Bell
AKAnthony R. Kerlavage
Anthony R. Kerlavage
Since 2014, the NCI has launched a series of data commons as part of the Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic, imaging, and clinical data to support cancer research and promote data sharing of NCI-funded studies. This review describes each data commons (Genomic Data Commons, Proteomic Data Commons, Integrated Canine Data Commons, Cancer Data Service, Imaging Data Commons, and Clinical and Translational Data Commons), including their unique and shared features, accomplishments, and challenges. Also discussed is how the CRDC data commons implement Findable, Accessible, Interoperable, Reusable (FAIR) principles and promote data sharing in support of the new NIH Data Management and Sharing Policy. See related articles by Brady et al., p. 1384, Pot et al., p. 1396, and Kim et al., p. 1404

15 March 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
EKErika Kim
Erika Kim
TDTanja M. Davidsen
Tanja M. Davidsen
BDBrandi N Davis-Dusenbery
Brandi N Davis-Dusenbery
ABAlexander Baumann
Alexander Baumann
AMAngela Maggio
Angela Maggio
AKAnthony R. Kerlavage
Anthony R. Kerlavage
More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations to better understand diseases and ultimately inform the development of better treatments and diagnostic tools. To enable the successful sharing and use of big data, the NCI developed the Cancer Research Data Commons (CRDC), providing access to a large, comprehensive, and expanding collection of cancer data. The CRDC is a cloud-based data science infrastructure that eliminates the need for researchers to download and store large-scale datasets by allowing them to perform analysis where data reside. Over the past 10 years, the CRDC has made significant progress in providing access to data and tools along with training and outreach to support the cancer research community. In this review, we provide an overview of the history and the impact of the CRDC to date, lessons learned, and future plans to further promote data sharing, accessibility, interoperability, and reuse. See related articles by Brady et al., p. 1384, Wang et al., p. 1388, and Pot et al., p. 1396

27 October 2025 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
MKMurat Kantarcioglu
Murat Kantarcioglu
WHWill Howe
Will Howe
BLBenmei Liu
Benmei Liu
VPValentina Petkov
Valentina Petkov
ECEsmeralda Casas-Silva
Esmeralda Casas-Silva
LPLynne Penberthy
Lynne Penberthy
Objective: The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) supports efforts to address critical challenges in advancing cancer research. As part of this effort, NCI sponsored the development of a privacy-preserving record linkage (PPRL) software that transforms identifying patient information into multiple tokens through a set of cryptographically secure keyed hash functions. This project aims to evaluate the PPRL software in the perspective of re-identification risks and propose effective strategies to sufficiently mitigate these risks. Materials and Methods: To achieve the goals, we developed a novel re-identification risk assessment framework, based on token frequency analysis, to estimate the privacy impact of hashed tokens shared for record linkage. We assessed privacy risk through empirical analysis on a state-level voter registration database, a public dataset commonly used for re-identification, under various scenarios. These scenarios are defined based on several factors, including the size of the dataset used for linkage and a group size parameter that determines when an adversary can claim that a record has been re-identified. Results: We found that the re-identification risk based on frequency analysis attack is approximately 0.0002 (ie, 2 patients out of 10 000 are potentially identifiable) under reasonable adversarial settings, with a group size parameter of k = 12 and a dataset size of 400 000 patients. Additionally, our analysis reveals a negative correlation between dataset size and re-identification risk. Discussion: Re-identification risk is deemed low for the new NCI PPRL software. Token frequency analysis provides a reliable estimate of the re-identification risk in token-based PPRL tools.